trending Market Intelligence /marketintelligence/en/news-insights/trending/AMe45CfxKBiXVY7S-5cTMw2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Alembic gets US FDA approval for 1st generic of Lilly's diabetes drug Jardiance

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Alembic gets US FDA approval for 1st generic of Lilly's diabetes drug Jardiance

Alembic Pharmaceuticals Ltd. secured tentative approval from the U.S. Food and Drug Administration to market a generic version of diabetes drug Jardiance that is co-marketed by Eli Lilly and Co. and Boehringer Ingelheim GmbH.

Gujarat, India-based Alembic's drug is the first generic of Jardiance to gain approval in the U.S.

Jardiance, or empagliflozin, was first approved by the FDA in 2014 to control blood sugar in patients with type 2 diabetes. The U.S. regulator expanded the indication in 2016 to lower the risk of cardiovascular death in adults with type 2 diabetes and cardiovascular disease.